Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
0.5374
Dollar change
-0.0026
Percentage change
-0.48
%
Index- P/E- EPS (ttm)-3.16 Insider Own0.50% Shs Outstand29.70M Perf Week-1.16%
Market Cap15.96M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float29.55M Perf Month-50.24%
Income11.39M PEG- EPS next Q- Inst Own6.77% Short Float3.77% Perf Quarter68.46%
Sales35.52M P/S0.45 EPS this Y- Inst Trans-38.42% Short Ratio0.11 Perf Half Y-46.26%
Book/sh0.88 P/B0.61 EPS next Y- ROA11.22% Short Interest1.11M Perf Year-93.89%
Cash/sh0.54 P/C0.99 EPS next 5Y- ROE- 52W Range0.26 - 9.76 Perf YTD-63.19%
Dividend Est.- P/FCF- EPS past 5Y15.13% ROI255.09% 52W High-94.49% Beta3.44
Dividend TTM- Quick Ratio0.78 Sales past 5Y226.69% Gross Margin39.59% 52W Low109.11% ATR (14)0.08
Dividend Ex-Date- Current Ratio0.96 EPS Y/Y TTM94.66% Oper. Margin-98.84% RSI (14)36.23 Volatility8.28% 10.12%
Employees123 Debt/Eq0.66 Sales Y/Y TTM-55.76% Profit Margin32.07% Recom1.00 Target Price40.00
Option/ShortNo / Yes LT Debt/Eq0.29 EPS Q/Q102.33% Payout- Rel Volume0.06 Prev Close0.54
Sales Surprise- EPS Surprise- Sales Q/Q-90.21% EarningsAug 17 BMO Avg Volume10.02M Price0.54
SMA20-6.22% SMA50-44.95% SMA200-51.78% Trades Volume600,872 Change-0.48%
Date Action Analyst Rating Change Price Target Change
Aug-31-21Initiated Cantor Fitzgerald Overweight $22
May-18-21Initiated H.C. Wainwright Buy $23
Sep-11-20Initiated BTIG Research Buy
Jul-12-19Upgrade WBB Securities Buy → Strong Buy
Mar-12-19Upgrade WBB Securities Speculative Buy → Buy
Jan-26-18Initiated Nomura Buy $18
Oct-06-17Initiated Seaport Global Securities Buy $19
Oct-04-17Reiterated H.C. Wainwright Buy $33 → $36
Feb-24-17Reiterated FBR & Co. Outperform $36 → $25
Jul-27-16Reiterated FBR Capital Outperform $33 → $36
Feb-20-24 07:00AM
Jan-26-24 12:46PM
Jan-25-24 09:05AM
06:00AM
Dec-20-23 08:45AM
07:00AM Loading…
Dec-12-23 07:00AM
Dec-04-23 07:00AM
Dec-03-23 01:11PM
Nov-30-23 09:08AM
Nov-27-23 01:41PM
07:00AM
Nov-14-23 08:00AM
Oct-03-23 07:00AM
Sep-22-23 04:15PM
Sep-18-23 07:00AM
07:00AM Loading…
Sep-05-23 07:00AM
Aug-17-23 07:00AM
Aug-01-23 07:00AM
Jul-31-23 07:00AM
Jul-25-23 03:58PM
Jul-21-23 09:33AM
07:00AM
Jun-12-23 08:00AM
May-22-23 07:00AM
May-15-23 06:17PM
May-09-23 07:00AM
May-01-23 07:00AM
Apr-28-23 07:00AM
Apr-17-23 07:39AM
Apr-11-23 07:00AM
01:26PM Loading…
Apr-03-23 01:26PM
Mar-30-23 08:00AM
Mar-23-23 07:32AM
Mar-21-23 07:00AM
Mar-16-23 06:15PM
Mar-08-23 07:05PM
Feb-28-23 08:01AM
07:00AM
Feb-16-23 08:01AM
08:00AM
Feb-15-23 07:00AM
Feb-10-23 03:10PM
Feb-06-23 07:00AM
Jan-26-23 07:00AM
Jan-03-23 11:07AM
07:00AM
Dec-27-22 02:53PM
Dec-07-22 09:45AM
Dec-06-22 01:36PM
Dec-02-22 09:00AM
Dec-01-22 04:01PM
Nov-29-22 08:00AM
Nov-24-22 05:19AM
Nov-17-22 08:30AM
Nov-15-22 03:09PM
Nov-14-22 08:59AM
07:00AM
06:00AM
Nov-13-22 07:33AM
Nov-07-22 09:49AM
Nov-04-22 07:00AM
Oct-30-22 08:58AM
Oct-27-22 07:45AM
Oct-26-22 07:00AM
Oct-20-22 01:08PM
Oct-19-22 12:34PM
07:00AM
Oct-18-22 07:00AM
Oct-03-22 11:20AM
07:00AM
Aug-18-22 11:04AM
Aug-17-22 10:12AM
08:00AM
Aug-10-22 08:17AM
Jul-12-22 08:00AM
Jun-24-22 05:31AM
Jun-23-22 01:01PM
07:00AM
Jun-17-22 08:30AM
May-25-22 09:15AM
May-10-22 07:37AM
May-09-22 08:30AM
May-06-22 11:20AM
May-04-22 03:17PM
Apr-14-22 09:55AM
Apr-11-22 09:00AM
08:02AM
Mar-17-22 07:59AM
Mar-15-22 09:00AM
Mar-10-22 07:00AM
Mar-03-22 04:10AM
Mar-02-22 04:18PM
Mar-01-22 12:00PM
09:00AM
Feb-17-22 09:30AM
Feb-07-22 01:38PM
10:15AM
Jan-18-22 01:38PM
Jan-13-22 11:51AM
10:35AM
RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. It operates through Commercial Operations, and the Research and Development segments. The Commercial Operations segment covers all areas relating to the commercial sales and is being performed by the subsidiary in the U.S. The Research and Development segment includes the study and licensing of therapeutic candidates. Its products include Talicia, Movantik, and Aemcolo. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.